Strota/ Newsroom/ 2026-06-30

AUROPHARMA (Aurobindo Pharma Ltd.): Acquisition / M&A

Strota Newsroom · session of 2026-06-30 · 30 Jun 09:57 · AUROPHARMA stock page →

Intimation of completion of Lannett acquisition by Aurobindo Pharma USA Inc., a wholly owned subsidiary of the Company. Historically, acquisition / m&a events have moved AUROPHARMA-type stocks in the bullish direction 48.9% of the next sessions (n=141).

Aurobindo Pharma Ltd. informed the exchange that its wholly owned subsidiary, Aurobindo Pharma USA Inc., has completed the acquisition of Lannett Company, according to an NSE filing dated 30 June 2026. The company had received US regulatory clearance for the $250 million deal earlier in the month. The stock closed at ₹1,547.5 on 29 June, down 0.62% from the previous session.

Events like this—completed acquisitions in the pharmaceutical sector—have historically shown a 48.9% win rate across 141 comparable instances tracked by Strota, with a net edge of 0.213 percentage points. This base rate reflects past market reactions to similar deal completions, not a forecast for this specific stock.

The counter is trading 3.3 times its average volume over the past sessions, with relative strength index at 65.4, indicating momentum near overbought territory. It sits 2.38% below its 52-week high of ₹1,585.3 and 52.3% above its 52-week low, holding above both its 50-day and 200-day moving averages. The company commands a market capitalisation of ₹90,162 crore, trades at a price-to-earnings multiple of 25.97, and carries a dividend yield of 0.26%. Futures and options positioning shows "Long Unwinding," with open interest declining 14.93%.

The data establishes that the acquisition has closed and that comparable events have historically produced mixed directional outcomes with slight positive edge. It does not establish whether the deal will expand earnings, how the stock will perform relative to the broader market, or whether current valuation levels are sustainable.

The catalyst

Intimation of completion of Lannett acquisition by Aurobindo Pharma USA Inc., a wholly owned subsidiary of the Company. (filing · NSE)

What the data shows after this event

Across Strota's backtest of past filings, Acquisition / M&A shows no reliable next-session edge — the move went bullish in about 48.9% of next sessions (net 0.213% after drift and cost, n=141). A base rate, not a forecast for this stock.

AUROPHARMA right now

F&O shows Long Unwinding (OI -14.93% ); P/E 25.97; RSI 65.4. Full AUROPHARMA analysis →

Sources

Intimation of completion of Lannett acquisition by Aurobindo Pharma USA Inc., a wholly owned subsidiary of the Company. — NSE
AUROPHARMA Share Price Today - Aurobindo Pharma on NSE/BSE — scanx.trade
Price to sales forward of Aurobindo Pharma Ltd – NSE:AUROPHARMA — TradingView
Aurobindo Pharma shares up 25% in 2026: Nuvama says 'Buy', ups target price; here's why — Business Today
Aurobindo Pharma shares in focus as US FTC clears $250 million Lannett acquisition — Business Today

Keep digging

AUROPHARMA — full smart-money page: F&O positioning, deals, insider filings and option chain in one place.
Today's screens: every stock matching the same setups (buildups, breakouts, volume shockers).
Newsroom: the other stocks in play this session.

How this article was made: Strota assembled the exchange data above (prices, F&O open interest, bulk/block deals, SEBI PIT filings, indicator readings and public headlines) and an AI model wrote the narrative strictly from that evidence — it is not permitted to add outside facts or numbers. Every figure comes from the underlying exchange/public data.